Key result
Adding ER niacin/laropiprant to statins increases definite myopathy risk ~340%, particularly in Chinese patients.
Why the study?
Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes in high-risk patients was uncertain.
Does extended release niacin/laropiprant increase the risk of myopathy and liver abnormalities when added to statin therapy in high-risk patients with occlusive arterial disease?
RCT (n=25,673)
randomized
Yes
Does extended release niacin/laropiprant increase the risk of myopathy and liver abnormalities when added to statin therapy in high-risk patients with occlusive arterial disease?
Answers are grounded in this paper and cite their sources.
Adding extended release niacin/laropiprant to simvastatin significantly increases the risk of myopathy, particularly in Chinese patients, and leads to higher rates of treatment discontinuation due to side effects.
AIMS: Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events. METHODS AND RESULTS: Prior to randomization, 42 424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required, ezetimibe 10 mg daily to standardize their low-density lipoprotein (LDL)-lowering therapy. The ability to remain compliant with ER niacin 2 g plus laropiprant 40 mg daily (ERN/LRPT) for ~1 month was then assessed in 38 369 patients and about one-third were excluded (mainly due to niacin side effects). A total of 25 673 patients were randomized between ERN/LRPT daily vs. placebo and were followed for a median of 3.9 years. By the end of the study, 25% of participants allocated ERN/LRPT vs. 17% allocated placebo had stopped their study treatment. The most common medical reasons for stopping ERN/LRPT were related to skin, gastrointestinal, diabetes, and musculoskeletal side effects. When added to statin-based LDL-lowering therapy, allocation to ERN/LRPT increased the risk of definite myopathy [75 (0.16%/year) vs. 17 (0.04%/year): risk ratio 4.4; 95% CI 2.6-7.5; P < 0.0001]; 7 vs. 5 were rhabdomyolysis. Any myopathy (definite or incipient) was more common among participants in China [138 (0.66%/year) vs. 27 (0.13%/year)] than among those in Europe [17 (0.07%/year) vs. 11 (0.04%/year)]. Consecutive alanine transaminase >3× upper limit of normal, in the absence of muscle damage, was seen in 48 (0.10%/year) ERN/LRPT vs. 30 (0.06%/year) placebo allocated participants. CONCLUSION: The risk of myopathy was increased by adding ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe), particularly in Chinese patients whose myopathy rates on simvastatin were higher. Despite the side effects of ERN/LRPT, among individuals who were able to tolerate it for ~1 month, three-quarters continued to take it for ~4 years.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2013) conducted an RCT in occlusive arterial disease (n=25,673). ER niacin/laropiprant vs. placebo was evaluated on definite myopathy (RR 4.4, 95% CI 2.6-7.5, p=< 0.0001). Adding ER niacin/laropiprant to statin therapy increased the risk of definite myopathy compared to placebo, particularly in Chinese patients.
Synapse has enriched 10 related papers. Consider them for comparative context: